on Theranexus (EPA:ALTHX)
THX Pharma: Allinvest Securities Recommends Buying the Stock
On June 16, 2026, Allinvest Securities announced that its stock had been covered. A research note highlights a 226% upside potential for the stock, with a price target of €10.40, compared to €3.205 on June 15.
This coverage highlights THX Pharma's strategic transformation, which has refocused on rare diseases with Batten-1 and TX01. Partnerships with Exeltis and Biocodex have strengthened its credibility and financial position, marking a significant change in its risk profile.
With this coverage, THX Pharma aims to increase its stock market visibility and reaffirm its commitment to transparent communication. It is now being followed by two financial analysis firms.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news